ALX-0171 Dose 1 + ALX-0171 Dose 2 + Placebo
Phase 2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Respiratory Syncytial Virus Lower Respiratory Tract Infection
Conditions
Respiratory Syncytial Virus Lower Respiratory Tract Infection
Trial Timeline
Feb 1, 2019 → May 1, 2020
NCT ID
NCT03468829About ALX-0171 Dose 1 + ALX-0171 Dose 2 + Placebo
ALX-0171 Dose 1 + ALX-0171 Dose 2 + Placebo is a phase 2 stage product being developed by Sanofi for Respiratory Syncytial Virus Lower Respiratory Tract Infection. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03468829. Target conditions include Respiratory Syncytial Virus Lower Respiratory Tract Infection.
What happened to similar drugs?
4 of 20 similar drugs in Respiratory Syncytial Virus Lower Respiratory Tract Infection were approved
Approved (4) Terminated (1) Active (15)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03468829 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Respiratory Syncytial Virus Lower Respiratory Tract Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1273 | Moderna | Phase 1 | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Phase 1 | 0 |
| mRNA-1345 | Moderna | Phase 2 | 0 |
| mRNA-1345 | Moderna | Phase 2 | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Preclinical | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Phase 1 | 0 |
| Zopapogene imadenovec (Zopa) | Precigen | Approved | 44 |
| PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2 | Precigen | Phase 1/2 | 30 |
| agenT-797 | MiNK Therapeutics | Phase 1 | 19 |
| YMC026 + Placebo | Yuhan | Approved | 43 |
| VN-0200 + Placebo | Daiichi Sankyo | Phase 1 | 29 |
| VN-0200 | Daiichi Sankyo | Phase 2 | 35 |
| Isavuconazonium Injection [Cresemba] + Placebo | Astellas Pharma | Phase 3 | 32 |
| S-337395 + Placebo | Shionogi | Phase 2 | 42 |
| Sivelestat | Eli Lilly | Phase 1/2 | 32 |